Is HUM a Buy? What to Consider in 2026
Short answer
The bull case for Humana (HUM) rests on Demographic tailwind in Medicare Advantage: The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. Revenue (TTM) is ~$130 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Whether HUM is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Humana Inc. is a Louisville-based health and well-being company best known as one of the two largest Medicare Advantage insurers in the country, alongside UnitedHealth. Its Insurance segment covers roughly 7.1 million individual and group Medicare Advantage members as of early 2026, plus Medicaid, military (TRICARE), and pharmacy-benefit members. The core economics turn on the medical loss ratio, the share of premium dollars paid out as medical claims, and on CMS star ratings, which determine quality-bonus payments that fund richer plan benefits.
What's the case for buying HUM?
Demographic tailwind in Medicare Advantage
The US population aged 65 and older keeps growing, and a rising share of seniors choose Medicare Advantage over traditional Medicare. Humana reported about 7.1 million Medicare Advantage members in early 2026, up roughly 22% year over year, and has targeted around 25% individual MA membership growth for the year. This long-run enrollment trend is the central reason the bull case exists.
CenterWell healthcare services
CenterWell combines pharmacy, senior primary care, and home health into a services arm that produced roughly $22.5 billion in revenue in 2025, with CenterWell Pharmacy alone near $13 billion. The strategy is to capture more of the healthcare dollar and coordinate care for Humana's own members, which can both add revenue and help manage medical costs over time.
Margin recovery and turnaround
After a period of elevated medical costs, management is targeting a multi-year margin rebuild, aiming to roughly double Medicare Advantage margin in 2026 and reach a sustainable level near 3% by 2028 through repricing plans, exiting unprofitable markets, and operating efficiency. The pace and durability of this recovery is the swing factor for future earnings.
Scale in government programs
Concentrating on Medicare Advantage, Medicaid, and TRICARE gives Humana scale, data, and provider relationships in government-funded health coverage. That focus removed the lower-margin commercial group business and lets the company specialize, though it also concentrates the model around policy and reimbursement decisions made by federal and state programs.
What are the risks to HUM?
The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Star ratings are a second lever, since a slip in ratings reduces CMS quality-bonus payments and can force benefit cuts that hurt retention; Humana's ratings softened heading into 2026. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing can pressure profitability or cause member attrition if benefits are trimmed too far.
How is HUM valued? (as of June 2026)
- Revenue (TTM): ~$130 billion
- Adjusted EPS (2026 guidance): ~$9.00 or more
- Medical loss ratio (2026 outlook): ~92.75%
- Dividend yield: ~1.5%
- Price/Earnings (TTM): ~40x
- Market capitalization: ~$45 billion
These figures are approximate and tied to the June 2026 asOf date; insurer earnings can move sharply quarter to quarter with the medical-cost trend, and the trailing P/E looks high mainly because recent profits are depressed. Check Humana's latest filings and a current quote before relying on any single number.
How do you decide if HUM is a buy?
Rather than asking whether HUM is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HUM indirectly through an index or sector ETF before adding more.
For the full picture, see the HUM stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HUM against your real portfolio and see your actual exposure before deciding.
The bottom line on HUM
The bottom line: Humana's story right now is Demographic tailwind in Medicare Advantage, with revenue (ttm) at ~$130 billion. If you believe that narrative continues, the call is about sizing HUM sensibly and checking overlap with what you own; if you doubt it (the risk: the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around HUM with Walnut
Use Humana as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is HUM a good stock to buy right now?
+
The case for Humana right now is Demographic tailwind in Medicare Advantage, with revenue (ttm) at ~$130 billion. If you believe that thesis holds, HUM is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Humana do?
+
Humana Inc.
What are the main risks of HUM?
+
The medical-cost trend is the dominant risk: when seniors use more care than priced for, the medical loss ratio rises and margins compress, which is what drove recent earnings pressure. Star ratings are a second lever, since a slip in ratings reduces CMS quality-bonus payments and can force benefit cuts that hurt retention; Humana's ratings softened heading into 2026. Medicare Advantage reimbursement and broader healthcare policy are set by the government and can change rate updates, risk-adjustment rules, or audit intensity. Finally, aggressive membership growth or repricing can pressure profitability or cause member attrition if benefits are trimmed too far.
Is HUM a good stock to buy right now?
+
That depends on your goals and risk tolerance, and this is not advice. The bull case is the aging-population tailwind, Humana's Medicare Advantage scale, CenterWell, and a margin recovery toward roughly 3% by 2028. The bear case is that medical costs, softer star ratings, and reimbursement changes have already pressured earnings and could keep margins thin. Weigh both and your own situation.
What does Humana do?
+
Humana is a health insurer focused on government programs, especially Medicare Advantage, where it covers about 7.1 million members. It also serves Medicaid and military TRICARE members. Through its CenterWell arm it operates pharmacy, senior primary care, and home-health businesses, aiming to coordinate care and capture more of the healthcare dollar for its own members.
Does HUM pay a dividend?
+
Yes. Humana pays a quarterly dividend of about $0.885 per share, which works out to roughly a 1.5% yield at a share price near $380 in mid-2026. The company has paid and generally raised its dividend for many consecutive years and also repurchases stock, though dividend policy can change with earnings and is set by the board.
Why did Humana stock drop?
+
Humana fell sharply from 2024 into 2025 as Medicare Advantage medical costs ran higher than priced, compressing margins and forcing earnings cuts. A downgrade in CMS star ratings reduced future quality-bonus payments, adding pressure. The stock hit a 52-week low near $163 before recovering toward $380 in 2026 as investors weighed the turnaround plan against ongoing cost and ratings risk.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell HUM; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.